New US venture aiming for novel oncology targets
This article was originally published in Scrip
A new drug discovery venture, FORMA Therapeutics, has been set up in the US, with a focus on the identification of novel oncology targets. Most of the co-founders come from the Broad Institute, a medical research initiative set up by Harvard University and the Massachusetts Institute of Technology with philanthropic funding.
You may also be interested in...
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.